WO2012164576A2 - Process for fosaprepitant - Google Patents
Process for fosaprepitant Download PDFInfo
- Publication number
- WO2012164576A2 WO2012164576A2 PCT/IN2012/000360 IN2012000360W WO2012164576A2 WO 2012164576 A2 WO2012164576 A2 WO 2012164576A2 IN 2012000360 W IN2012000360 W IN 2012000360W WO 2012164576 A2 WO2012164576 A2 WO 2012164576A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- siliabond
- solvent
- tert
- reaction mass
- fosaprepitant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Definitions
- the present invention provides a novel process for reducing palladium content in fosaprepitant dimeglumine.
- Fosaprepitant chemically [3- ⁇ [(2i?,35)-2-[(l/?)-l-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)mo ⁇ holin-4-yl]methyl ⁇ -5-oxo-2H-l,2,4-triazol- l- yl]phosphonic acid and has the structural formula:
- Fosaprepitant dimeglumine is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant dimeglumine is commercially available as a prescription medicine from Merck & Co, under the trade name EMEND® in US and IVEMEND® in Europe.
- fosaprepitant dimeglumine can be prepared by subjecting the solution of dibenzyl ⁇ 3-[2(R)-[(lR)-l-[3,5- bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)morpholin-4-yl]-5-oxo-4,5- dihydro-[l,2,4]-triazol-l-yl ⁇ phosphonic acid (herein after referred as dibenzyl fosaprepitant) in methanol or tetrahydrofuran to hydrogenation in the presence of palladium carbon and N-methyl-D-glucamine.
- fosaprepitant dimeglumine can be prepared by subjecting the solution of dibenzyl fosaprepitant in a solvent such as methanol, ethanol, isopropanol, methyl tert-butyl ether or tetrahydrofuran to hydrogenation in the presence of palladium carbon and N-methyl-D-glucamine.
- a solvent such as methanol, ethanol, isopropanol, methyl tert-butyl ether or tetrahydrofuran
- the fosaprepitant dimeglumine produced according to the prior art procedures contains palladium content of above 30 parts per million (ppm).
- an object of the present invention is to provide a novel process for reducing palladium content in fosaprepitant dimeglumine.
- the present invention provides a novel process for reducing palladium content in fosaprepitant dimeglumine, which comprises:
- step (b) adding SiliaBond Metal Scavenger to the solution obtained in step (a);
- step (e) slurring the wet solid obtained in step (e) with an ester solvent
- the present invention provides a novel process for reducing palladium content in fosaprepitant dimeglumine, which comprises:
- step (b) adding SiliaBond Metal Scavenger to the reaction mass obtained in step (b);
- step (e) adding nitrile solvent to the residual solid obtained in step (e);
- room temperature refers to temperature at about 25 to 35°C.
- a novel process for reducing palladium content in fosaprepitant dimeglumine which comprises: a) providing a solution of fosaprepitant dimeglumine in a solvent;
- step (b) adding SiliaBond Metal Scavenger to the solution obtained in step (a);
- step (e) slurring the wet solid obtained in step (e) with an ester solvent
- the solvent used in step (a) and step (d) may preferably be a solvent or mixture of solvents selected form methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, n-butanol, isobutyl alcohol, tetrahydrofuran, diisopropyl ether, tertrahydropyran, 1,4-dioxane, methyl tert-butyl ether, ethyl tert-butyl ether, diethyl ether, di-tert-butyl ether, diglyme, dimethoxyethane, dimethoxymethane and methoxyethane. More preferably the solvents are methanol, ethanol, isopropyl alcohol and teterahydrofuran.
- Standard Metal Scavenger is used for removing residual metals from post reactions.
- the toxic nature of transition metals has led to the reduction of tolerated residual concentration in active pharmaceutical ingredients (APIs) to single digit ppm.
- the SiliaBond Metal Scavenger used in step (b) may be selected from SiliaBond amine, SiliaBond diamine, SiliaBond Triaminetetraacetic Acid, SiliaBond Thiol, SiliaBond Thiourea, SiliaBond propyl bromide and SiliaBond dimercaptotriazine. More preferably the SiliaBond Metal Scavenger is SiliaBond dimercaptotriazine.
- the step (c) may conveniently be carried out at room temperature.
- the ester solvent used in step (f) may be a solvent or mixture of solvents selected from ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate and ethyl formate. More preferably the ester solvent is ethyl acetate.
- Isolation of fosaprepitant dimeglumine in step (g) may preferably be performed by conventional techniques such as centrifugation and filtration.
- a novel process for reducing palladium content in fosaprepitant dimeglumine which comprises: a) providing a solution of dibenzyl fosaprepitant in a solvent;
- step (b) adding SiliaBond Metal Scavenger to the reaction mass obtained in step (b);
- step (e) adding nitrile solvent to the residual solid obtained in step (e);
- the solvent used in step (a) may preferably be a solvent or mixture of solvents selected form methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, n-butanol, isobutyl alcohol, tetrahydrofuran, diisopropyl ether, tertrahydropyran, 1,4-dioxane, methyl tert- butyl ether, ethyl tert-butyl ether, diethyl ether, di-tert-butyl ether, diglyme, dimethoxyethane, dimethoxymethane and methoxyethane. More preferably the solvents are methanol, ethanol, isopropyl alcohol and teterahydrofuran.
- SiliaBond Metal Scavenger used in step (c) may be selected from
- SiliaBond amine SiliaBond diamine, SiliaBond Triaminetetraacetic Acid, SiliaBond Thiol, SiliaBond Thiourea, SiliaBond propyl bromide and SiliaBond dimercaptotriazine. More preferably the SiliaBond Metal Scavenger is SiliaBond dimercaptotriazine.
- step (d) may conveniently be carried out at room temperature. Removal of the solvent in step (e) may be carried out at atmospheric pressure or at reduced pressure. Removal of the solvent may preferably be carried out until the solvent is almost completely distilled off.
- the nitrile solvent used in step (f) may be a solvent or mixture of solvents selected from acetonitrile, propionitrile, butyronitrile and benzonitrile. More preferably the nitrile solvent is acetonitrile.
- Isolation of fosaprepitant dimeglumine in step (g) may preferably be performed by conventional techniques such as centrifugation and filtration.
- Dibenzyl fosaprepitant 50 gm as obtained in preparative example 1, N-methyl- D-glucamine (25 gm), palladium carbon (10 gm) and methanol (410 gm) were added at room temperature and then applied 40 percent hydrogen pressure for 5 hours.
- the reaction mass was filtered through hyflow-bed and the solvent was distilled off under vacuum pressure at 30 to 35 C to obtain a residual solid.
- the residual solid obtained was co-distilled with isopropyl alcohol and acetonitrile.
- To the reaction mass was added acetonitrile (200 ml) under nitrogen atmosphere and stirred for 15 hours at room temperature.
- the solid obtained was collected by filtration and dried to obtain 29 gm of fosaprepitant dimeglumine (Palladium content: 30 ppm).
- Fosaprepitant dimeglumine (10 gm; Palladium content: 30 ppm) as obtained in preparative example 2 was dissolved in methanol (100 ml) and stirred for 15 minutes to obtain a solution.
- SiliaBond dimercaptotriazine (1 gm) was added to the solution.
- the reaction mass was filtered through hyflow-bed and washed with methanol.
- isopropyl alcohol 375 ml
- the reaction mass was stirred for 1 hour at 20 to 25°C and filtered.
- To the wet solid thus obtained was added ethyl acetate (100 ml) and maintained for 1 hour.
- the separated solid was filtered and dried to obtain 8 gm of fosaprepitant dimeglumine (Palladium content: 2 ppm).
- Dibenzyl fosaprepitant 50 gm
- N-methyl-D-glucamine 25 gm
- palladium carbon 10 gm
- methanol 410 gm
- the reaction mass was filtered through hyflow- bed.
- SiliaBond dimercaptotriazine 5 gm
- the reaction mass was filtered through hyflow-bed and the solvent was distilled off under vacuum pressure at 30 to 35°C to obtain a residual solid.
- the residual solid obtained was co-distilled with isopropyl alcohol and acetonitrile.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Catalysts (AREA)
Abstract
The present invention provides a novel process for reducing palladium content in fosaprepitant dimeglumine.
Description
PROCESS FOR FOSAPREPITANT
This application claims the benefit of Indian Patent Application No. 1927/CHE/201 1 , filed on June 03, 201 1, which is incorporated herein by reference.
Filed of the Invention
The present invention provides a novel process for reducing palladium content in fosaprepitant dimeglumine.
Background of the Invention
Fosaprepitant, chemically [3-{[(2i?,35)-2-[(l/?)-l-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)moφholin-4-yl]methyl}-5-oxo-2H-l,2,4-triazol- l- yl]phosphonic acid and has the structural formula:
Fosaprepitant dimeglumine is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant dimeglumine is commercially available as a prescription medicine from Merck & Co, under the trade name EMEND® in US and IVEMEND® in Europe.
Fosaprepitant dimeglumine and its process were disclosed in U.S. patent no. 5,691 ,336.
PCT publication no. WO 2010/018595 disclosed a process for the purification of fosaprepitarit dimeglumine. According to the publication, fosaprepitant dimeglumine can
be prepared by subjecting the solution of dibenzyl {3-[2(R)-[(lR)-l-[3,5- bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)morpholin-4-yl]-5-oxo-4,5- dihydro-[l,2,4]-triazol-l-yl} phosphonic acid (herein after referred as dibenzyl fosaprepitant) in methanol or tetrahydrofuran to hydrogenation in the presence of palladium carbon and N-methyl-D-glucamine.
PCT publication no. WO 2011/045817 disclosed a process for the preparation of fosaprepitant dimeglumine. According to the publication, fosaprepitant dimeglumine can be prepared by subjecting the solution of dibenzyl fosaprepitant in a solvent such as methanol, ethanol, isopropanol, methyl tert-butyl ether or tetrahydrofuran to hydrogenation in the presence of palladium carbon and N-methyl-D-glucamine.
It has been found that the fosaprepitant dimeglumine produced according to the prior art procedures contains palladium content of above 30 parts per million (ppm). The desired product for reduction of tolerated residual concentration to single digit ppm. There is a need for a reproducible process for the preparation of fosaprepitant dimeglumine.
Thus, an object of the present invention is to provide a novel process for reducing palladium content in fosaprepitant dimeglumine.
Summary of the Invention
In one aspect, the present invention provides a novel process for reducing palladium content in fosaprepitant dimeglumine, which comprises:
a) providing a solution of fosaprepitant dimeglumine in a solvent;
b) adding SiliaBond Metal Scavenger to the solution obtained in step (a);
c) maintaining the reaction mass obtained in step (b);
d) adding a solvent to the reaction mass;
e) isolating the wet solid;
f) slurring the wet solid obtained in step (e) with an ester solvent; and
g) isolating fosaprepitant dimeglumine.
In another aspect, the present invention provides a novel process for reducing palladium content in fosaprepitant dimeglumine, which comprises:
a) providing a solution of dibenzyl fosaprepitant in a solvent;
b) subjecting the solution to hydrogenation in the presence of palladium carbon and N-methyl-D-glucamine;
c) adding SiliaBond Metal Scavenger to the reaction mass obtained in step (b);
d) maintaining the reaction mass;
e) removing the solvent from the reaction mass to obtain a residual solid;
f) adding nitrile solvent to the residual solid obtained in step (e); and
g) isolating fosaprepitant dimeglumine.
Detailed Description of the Invention
The term "room temperature" refers to temperature at about 25 to 35°C.
According to one aspect of the present invention, there is provided a novel process for reducing palladium content in fosaprepitant dimeglumine, which comprises: a) providing a solution of fosaprepitant dimeglumine in a solvent;
b) adding SiliaBond Metal Scavenger to the solution obtained in step (a);
c) maintaining the reaction mass obtained in step (b);
d) adding a solvent to the reaction mass;
e) isolating the wet solid;
f) slurring the wet solid obtained in step (e) with an ester solvent; and
g) isolating fosaprepitant dimeglumine.
The solvent used in step (a) and step (d) may preferably be a solvent or mixture of solvents selected form methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, n-butanol, isobutyl alcohol, tetrahydrofuran, diisopropyl ether, tertrahydropyran, 1,4-dioxane, methyl tert-butyl ether, ethyl tert-butyl ether, diethyl ether, di-tert-butyl ether, diglyme, dimethoxyethane, dimethoxymethane and methoxyethane. More preferably the solvents are methanol, ethanol, isopropyl alcohol and teterahydrofuran.
The term "SiliaBond Metal Scavenger" is used for removing residual metals from post reactions. The toxic nature of transition metals has led to the reduction of tolerated residual concentration in active pharmaceutical ingredients (APIs) to single digit ppm.
Preferably the SiliaBond Metal Scavenger used in step (b) may be selected from SiliaBond amine, SiliaBond diamine, SiliaBond Triaminetetraacetic Acid, SiliaBond
Thiol, SiliaBond Thiourea, SiliaBond propyl bromide and SiliaBond dimercaptotriazine. More preferably the SiliaBond Metal Scavenger is SiliaBond dimercaptotriazine.
The step (c) may conveniently be carried out at room temperature.
Preferably the ester solvent used in step (f) may be a solvent or mixture of solvents selected from ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate and ethyl formate. More preferably the ester solvent is ethyl acetate.
Isolation of fosaprepitant dimeglumine in step (g) may preferably be performed by conventional techniques such as centrifugation and filtration.
According to another aspect of the present invention, there is provided a novel process for reducing palladium content in fosaprepitant dimeglumine, which comprises: a) providing a solution of dibenzyl fosaprepitant in a solvent;
b) subjecting the solution to hydrogenation in the presence of palladium carbon and N-methyl-D-glucamine;
c) adding SiliaBond Metal Scavenger to the reaction mass obtained in step (b);
d) maintaining the reaction mass;
e) removing the solvent from the reaction mass to obtain a residual solid;
f) adding nitrile solvent to the residual solid obtained in step (e); and
g) isolating fosaprepitant dimeglumine.
The solvent used in step (a) may preferably be a solvent or mixture of solvents selected form methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, n-butanol, isobutyl alcohol, tetrahydrofuran, diisopropyl ether, tertrahydropyran, 1,4-dioxane, methyl tert- butyl ether, ethyl tert-butyl ether, diethyl ether, di-tert-butyl ether, diglyme, dimethoxyethane, dimethoxymethane and methoxyethane. More preferably the solvents are methanol, ethanol, isopropyl alcohol and teterahydrofuran.
Preferably the SiliaBond Metal Scavenger used in step (c) may be selected from
SiliaBond amine, SiliaBond diamine, SiliaBond Triaminetetraacetic Acid, SiliaBond Thiol, SiliaBond Thiourea, SiliaBond propyl bromide and SiliaBond dimercaptotriazine. More preferably the SiliaBond Metal Scavenger is SiliaBond dimercaptotriazine.
The step (d) may conveniently be carried out at room temperature.
Removal of the solvent in step (e) may be carried out at atmospheric pressure or at reduced pressure. Removal of the solvent may preferably be carried out until the solvent is almost completely distilled off.
Preferably the nitrile solvent used in step (f) may be a solvent or mixture of solvents selected from acetonitrile, propionitrile, butyronitrile and benzonitrile. More preferably the nitrile solvent is acetonitrile.
Isolation of fosaprepitant dimeglumine in step (g) may preferably be performed by conventional techniques such as centrifugation and filtration.
The invention will now be further described by the following examples, which are illustrative rather than limiting.
Preparative examples
Preparative example 1:
Preparation of dibenzyl fosaprepitant
Aprepitant (50 gm), tetrabenzyl pyrophosphate (75 gm) and teterahydrofuran (635 ml) were added under nitrogen atmosphere at room temperature. The contents were then cooled to 0 to 5°C and then added sodium hexamethyldisilazane (266.6 ml) slowly for 45 minutes. The reaction mass was stirred for 30 minutes at 0 to 5°C and then added sodium bicarbonate solution (8%, 1700 ml) and methyl tert-butyl ether (1700 ml) at room temperature. The layers were separated and the organic layer was washed with saturated sodium hydrogen sulfite solution. Again the layers were separated and the organic layer was washed with water. The organic layer was dried with sodium sulfate and the solvent was distilled off under vacuum at 30 to 35°C to obtain 68 gm of dibenzyl fosaprepitant.
Preparative example 2:
Preparation of fosaprepitant dimeglumine
Dibenzyl fosaprepitant (50 gm) as obtained in preparative example 1, N-methyl- D-glucamine (25 gm), palladium carbon (10 gm) and methanol (410 gm) were added at room temperature and then applied 40 percent hydrogen pressure for 5 hours. The reaction mass was filtered through hyflow-bed and the solvent was distilled off under
vacuum pressure at 30 to 35 C to obtain a residual solid. The residual solid obtained was co-distilled with isopropyl alcohol and acetonitrile. To the reaction mass was added acetonitrile (200 ml) under nitrogen atmosphere and stirred for 15 hours at room temperature. The solid obtained was collected by filtration and dried to obtain 29 gm of fosaprepitant dimeglumine (Palladium content: 30 ppm).
Examples
Example 1:
Fosaprepitant dimeglumine (10 gm; Palladium content: 30 ppm) as obtained in preparative example 2 was dissolved in methanol (100 ml) and stirred for 15 minutes to obtain a solution. To the solution was added SiliaBond dimercaptotriazine (1 gm) and then maintained for 16 hours at room temperature. The reaction mass was filtered through hyflow-bed and washed with methanol. To the filtrate thus obtained was added isopropyl alcohol (375 ml) slowly for 1 hour. The reaction mass was stirred for 1 hour at 20 to 25°C and filtered. To the wet solid thus obtained was added ethyl acetate (100 ml) and maintained for 1 hour. The separated solid was filtered and dried to obtain 8 gm of fosaprepitant dimeglumine (Palladium content: 2 ppm).
Example 2:
Dibenzyl fosaprepitant (50 gm), N-methyl-D-glucamine (25 gm), palladium carbon (10 gm) and methanol (410 gm) were added at room temperature and then applied 40 percent hydrogen pressure for 5 hours. The reaction mass was filtered through hyflow- bed. To the filtrate thus obtained was added SiliaBond dimercaptotriazine (5 gm) and maintained for 15 hours at room temperature. The reaction mass was filtered through hyflow-bed and the solvent was distilled off under vacuum pressure at 30 to 35°C to obtain a residual solid. The residual solid obtained was co-distilled with isopropyl alcohol and acetonitrile. To the reaction mass was added acetonitrile (200 ml) under nitrogen atmosphere and stirred for 15 hours at room temperature. The solid obtained was
collected by filtration and dried to obtain 28 gm of fosaprepitant dimeglumine (Palladium content: 3 ppm).
Example 3:
A solution of fosaprepitant dimeglumine (30 gm; Palladium content: 3 ppm) as obtained in example 2 in methanol (300 ml) was added to isopropyl alcohol (600 ml) slowly for 45 minutes at room temperature. The reaction mass was stirred for 1 hour at 20 to 25°C and filtered. The solid thus obtained was added to ethyl acetate (250 ml) and maintained for 1 hour at room temperature. The separated solid was filtered and dried to obtain 24 gm of fosaprepitant dimeglumine (Palladium content: 3 ppm).
Claims
1. A process for reducing palladium content in fosaprepitant dimeglumine, which comprises:
a. providing a solution of fosaprepitant dimeglumine in a solvent;
b. adding SiliaBond Metal Scavenger to the solution obtained in step (a);
c. maintaining the reaction mass obtained in step (b);
d. adding a solvent to the reaction mass;
e. isolating the wet solid;
f. slurring the wet solid obtained in step (e) with an ester solvent; and
g. isolating fosaprepitant dimeglumine.
2. The process as claimed in claim 1, wherein the solvent used in step (a) and step (d) is a solvent or mixture of solvents selected form methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, n-butanol, isobutyl alcohol, tetrahydrofuran, diisopropyl ether, tertrahydropyran, 1,4-dioxane, methyl tert-butyl ether, ethyl tert-butyl ether, diethyl ether, di-tert-butyl ether, diglyme, dimethoxyethane, dimethoxymethane and methoxyethane.
3. The process as claimed in claim 2, wherein the solvents are methanol, ethanol, isopropyl alcohol and teterahydrofuran.
4. The process as claimed in claim 1, wherein the SiliaBond Metal Scavenger used in step (b) is selected from SiliaBond amine, SiliaBond diamine, SiliaBond
Triaminetetraacetic Acid, SiliaBond Thiol, SiliaBond Thiourea, SiliaBond propyl bromide and SiliaBond dimercaptotriazine.
5. The process as claimed in claim 4, wherein the SiliaBond Metal Scavenger is SiliaBond dimercaptotriazine.
6. The process as claimed in claim 1, wherein the step (c) is carried out at room temperature.
7. The process as claimed in claim 1, wherein the ester solvent used in step (f) is a solvent or mixture of solvents selected from ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate and ethyl formate.
8. The process as claimed in claim 7, wherein the ester solvent is ethyl acetate.
9. A process for reducing palladium content in fosaprepitant dimeglumine, which comprises:
a. providing a solution of dibenzyl fosaprepitant in a solvent;
b. subjecting the solution to hydrogenation in the presence of palladium carbon and N-methyl-D-glucamine;
c. adding SiliaBond Metal Scavenger to the reaction mass obtained in step (b);
d. maintaining the reaction mass;
e. removing the solvent from the reaction mass to obtain a residual solid;
f. adding nitrile solvent to the residual solid obtained in step (e); and
g. isolating fosaprepitant dimeglumine.
10. The process as claimed in claim 9, wherein the solvent used in step (a) is a solvent or mixture of solvents selected form methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, n-butanol, isobutyl alcohol, tetrahydrofuran, diisopropyl ether, tertrahydropyran, 1,4-dioxane, methyl tert-butyl ether, ethyl tert-butyl ether, diethyl ether, di-tert-butyl ether, diglyme, dimethoxyethane, dimethoxymethane and methoxyethane.
11. The process as claimed in claim 10, wherein the solvents are methanol, ethanol, isopropyl alcohol and teterahydrofuran.
12. The process as claimed in claim 9, wherein the SiliaBond Metal Scavenger used in step (c) is selected from SiliaBond amine, SiliaBond diamine, SiliaBond
Triaminetetraacetic Acid, SiliaBond Thiol, SiliaBond Thiourea, SiliaBond propyl bromide and SiliaBond dimercaptotriazine.
13. The process as claimed in claim 12, wherein the SiliaBond Metal Scavenger is SiliaBond dimercaptotriazine.
14. The process as claimed in claim 9, wherein the step (d) is carried out at room temperature.
15. The process as claimed in claim 9, wherein the nitrile solvent used in step (f) is a solvent or mixture of solvents selected from acetonitrile, propionitrile, butyronitrile and benzonitrile.
16. The process as claimed in claim 15, wherein the nitrile solvent is acetonitrile.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/123,290 US9540406B2 (en) | 2011-06-03 | 2012-05-21 | Process for fosaprepitant |
| ES12793409.9T ES2594828T3 (en) | 2011-06-03 | 2012-05-21 | Procedure for fosaprepitant |
| EP12793409.9A EP2714701B1 (en) | 2011-06-03 | 2012-05-21 | Process for fosaprepitant |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1927/CHE/2011 | 2011-06-03 | ||
| IN1927CH2011 IN2011CH01927A (en) | 2011-06-03 | 2012-05-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2012164576A2 true WO2012164576A2 (en) | 2012-12-06 |
| WO2012164576A3 WO2012164576A3 (en) | 2013-03-28 |
Family
ID=47260000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2012/000360 Ceased WO2012164576A2 (en) | 2011-06-03 | 2012-05-21 | Process for fosaprepitant |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9540406B2 (en) |
| EP (1) | EP2714701B1 (en) |
| ES (1) | ES2594828T3 (en) |
| IN (1) | IN2011CH01927A (en) |
| WO (1) | WO2012164576A2 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20130744A1 (en) * | 2013-05-08 | 2014-11-09 | Olon Spa | PROCEDURE FOR THE PREPARATION OF FOSAPREPITANT DIMEGLUMINA |
| CN104650141A (en) * | 2013-11-22 | 2015-05-27 | 上海汇伦生命科技有限公司 | Refining method of fosaprepitant dimeglumine |
| CN104650142A (en) * | 2013-11-25 | 2015-05-27 | 山东新时代药业有限公司 | Preparation method of fosaprepitant dimeglumine |
| WO2015083033A1 (en) * | 2013-12-02 | 2015-06-11 | Piramal Enterprises Limited | An improved process for the preparation of fosaprepitant having improved purity |
| CN105254668A (en) * | 2013-05-14 | 2016-01-20 | 北京百川汇德医药技术开发有限公司 | New preparation method for fosaprepitant and pharmaceutically acceptable salt thereof |
| CN106588989A (en) * | 2016-11-08 | 2017-04-26 | 山东裕欣药业有限公司 | Novel crystal form of fosaprepitant dual-meglumine compound and preparing method thereof |
| WO2017093899A1 (en) | 2015-12-01 | 2017-06-08 | Piramal Enterprises Limited | A process for preparation of fosaprepitant dimeglumine and an intermediate thereof |
| TWI659039B (en) * | 2014-05-21 | 2019-05-11 | 台灣神隆股份有限公司 | A process of making fosaprepitant dimeglumine |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105294547A (en) * | 2014-07-30 | 2016-02-03 | 连云港宏创药业有限公司 | Method for removing palladium from perampanel crude product |
| US9850267B2 (en) | 2015-06-03 | 2017-12-26 | Navinta, Llc | Crystalline fosaprepitant dicyclohexylamine salt and its preparation |
| US9913853B2 (en) * | 2015-11-03 | 2018-03-13 | Cipla Limited | Stabilized liquid fosaprepitant formulations |
| CN107176964B (en) * | 2016-03-09 | 2019-09-20 | 杭州九源基因工程有限公司 | A kind of refining process for removing palladium of fosaprepitant |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8623844B2 (en) | 2008-07-17 | 2014-01-07 | Navin Ganesh Bhatt | Fosaprepitant dimeglumine intermediate, neutral fosaprepitant, and amorphous fosaprepitant dimeglumine and processes for their preparations |
| EP2342221B1 (en) | 2008-09-22 | 2018-11-07 | Aileron Therapeutics, Inc. | Methods for preparing purified polypeptide compositions |
| WO2011045817A2 (en) | 2009-10-15 | 2011-04-21 | Sandoz Private Limited | Process for the preparation of fosaprepitant, intermediate and pharmaceutical acceptable salt thereof |
-
2012
- 2012-05-21 WO PCT/IN2012/000360 patent/WO2012164576A2/en not_active Ceased
- 2012-05-21 EP EP12793409.9A patent/EP2714701B1/en not_active Not-in-force
- 2012-05-21 US US14/123,290 patent/US9540406B2/en active Active
- 2012-05-21 IN IN1927CH2011 patent/IN2011CH01927A/en unknown
- 2012-05-21 ES ES12793409.9T patent/ES2594828T3/en active Active
Non-Patent Citations (2)
| Title |
|---|
| None |
| See also references of EP2714701A4 |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20130744A1 (en) * | 2013-05-08 | 2014-11-09 | Olon Spa | PROCEDURE FOR THE PREPARATION OF FOSAPREPITANT DIMEGLUMINA |
| CN105254668A (en) * | 2013-05-14 | 2016-01-20 | 北京百川汇德医药技术开发有限公司 | New preparation method for fosaprepitant and pharmaceutically acceptable salt thereof |
| CN104650141A (en) * | 2013-11-22 | 2015-05-27 | 上海汇伦生命科技有限公司 | Refining method of fosaprepitant dimeglumine |
| CN104650142A (en) * | 2013-11-25 | 2015-05-27 | 山东新时代药业有限公司 | Preparation method of fosaprepitant dimeglumine |
| CN104650142B (en) * | 2013-11-25 | 2018-06-22 | 山东新时代药业有限公司 | A kind of preparation method of fosaprepitant dimeglumine |
| WO2015083033A1 (en) * | 2013-12-02 | 2015-06-11 | Piramal Enterprises Limited | An improved process for the preparation of fosaprepitant having improved purity |
| TWI659039B (en) * | 2014-05-21 | 2019-05-11 | 台灣神隆股份有限公司 | A process of making fosaprepitant dimeglumine |
| WO2017093899A1 (en) | 2015-12-01 | 2017-06-08 | Piramal Enterprises Limited | A process for preparation of fosaprepitant dimeglumine and an intermediate thereof |
| EP3383829A4 (en) * | 2015-12-01 | 2019-05-01 | Piramal Enterprises Limited | A process for preparation of fosaprepitant dimeglumine and an intermediate thereof |
| CN106588989A (en) * | 2016-11-08 | 2017-04-26 | 山东裕欣药业有限公司 | Novel crystal form of fosaprepitant dual-meglumine compound and preparing method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| IN2011CH01927A (en) | 2015-10-02 |
| ES2594828T3 (en) | 2016-12-22 |
| EP2714701A2 (en) | 2014-04-09 |
| EP2714701A4 (en) | 2014-12-24 |
| US9540406B2 (en) | 2017-01-10 |
| WO2012164576A3 (en) | 2013-03-28 |
| US20140107337A1 (en) | 2014-04-17 |
| EP2714701B1 (en) | 2016-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2714701B1 (en) | Process for fosaprepitant | |
| US7915407B2 (en) | Process for {3-[2(R)-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)morpholin-4-yl]methyl]-5-oxo-4,5-dihydro-[1,2,4]-triazol-1-yl}phosphonic acid | |
| CN1085213C (en) | Triazole derivatives useful in therapy | |
| CA3126268C (en) | Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched pcta and preparation and purification process | |
| JP6126251B2 (en) | Phenylcarbamate compound and composition for prevention or treatment of diseases caused by nerve gas containing the same {PHENYLCARBAMATECOMPOUNDANDACOMPOSITIONFORVENTINGTREATTINGGANERVEGAS-INDUCEDDISEASECOMPRISINGTHEME} | |
| JP2013534536A5 (en) | ||
| CA2794684A1 (en) | Process for preparing benzoxaboroles | |
| CN108137446A (en) | Anthracene -9,10- dione dioxime compound prodrug and application thereof | |
| CN102850398B (en) | Fosaprepitant preparation method | |
| JPH0395195A (en) | Substituted aminoalkylphosphinic acid | |
| US20120135965A1 (en) | Amorphous fosamprenavir calcium | |
| CN111138421A (en) | Antifungal water-soluble compound and preparation method and application thereof | |
| EP2986619A1 (en) | Process for the preparation of bortezomib mannitol ester | |
| WO2015083033A1 (en) | An improved process for the preparation of fosaprepitant having improved purity | |
| CN104230991A (en) | Method for controlling palladium residue in fosaprepitant dimeglumine | |
| WO2007080470A2 (en) | A method for the purification of levetiracetam | |
| EP3383829B1 (en) | A process for preparation of fosaprepitant dimeglumine and an intermediate thereof | |
| CN117088852A (en) | Preparation and palladium removal method of crizotinib intermediate | |
| WO2017093973A1 (en) | Process for the preparation of pure sofosbuvir | |
| CA2795741A1 (en) | Novel synthesis process for ivabradine and its addition salts to a pharmaceutically acceptable acid | |
| CN113583044B (en) | Preparation method of medicine for preventing chemotherapy-related nausea and vomiting | |
| CN104098604B (en) | A kind of method preparing fosaprepitant dimeglumine | |
| Głowacka et al. | Synthesis of the four enantiomers of diethyl 1, 2-di (N-Boc-amino) propylphosphonates | |
| WO2012131541A1 (en) | A process for the isolation of emtricitabine | |
| JPS6365053B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12793409 Country of ref document: EP Kind code of ref document: A2 |
|
| REEP | Request for entry into the european phase |
Ref document number: 2012793409 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 14123290 Country of ref document: US Ref document number: 2012793409 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |